Diffusion Pharmaceuticals Inc. (DFFN)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Diffusion Pharmaceuticals Inc. ("Diffusion" or the "Company") (NASDAQ: DFFN). The investigation concerns whether Diffusion and certain of its officers and/or directors have violated federal securities laws.
On July 27, 2020, Diffusion issued a press release “announc[ing] receipt of guidance from the U.S. Food and Drug Administration (FDA) on the Company’s recently-filed Investigational New Drug (IND) application for trans sodium crocetinate (TSC) in COVID-19 patients.” The press release specifically advised investors that “[t]his guidance suggests certain study design changes with regard to endpoints and statistical considerations that Diffusion believes will enhance the prospect of regulatory approvals upon program completion, should the clinical results be favorable.” On this news, Diffusion’s stock price fell $0.18 per share, or 12.64%, to close at $1.14 per share on July 27, 2020.
If you are aware of any facts relating to this investigation, or purchased Diffusion shares, you can assist this investigation by contacting the firm. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.